Gideon St. Helen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gideon St. Helen has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Peyton Jacob
Research Program in Clinical Pharmacology, Division of Cardiology, Department of Medicine, University of California, San Francisco, CA, USA
9 shared publications- Neal L. Benowitz
Department of Medicine University of California San Francisco California USA
7 shared publications Neal L. Benowitz
Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Med, Div Cardiol,Clin Pharmacol Res Program, Box 1220, San Francisco, CA 94143 USA
6 shared publications- Newton Addo
University of California San Francisco, Department of Emergency Medicine, San Francisco, California
5 shared publications Delia A. Dempsey
Clinical Pharmacology Research Program, Division of Cardiology, Zuckerberg San Francisco General, Department of Medicine, University of California, San Francisco, CA 94143-1220, USA
4 shared publicationsChristopher Havel
Research Program in Clinical Pharmacology, Division of Cardiology, Department of Medicine, University of California, San Francisco, CA, USA
3 shared publications
Latest Publications
- Open Access
- 1 November 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (11) , 2021-2042
Effects of Inhaled Tobacco and Cannabis Co-Use on Respiratory Health and Tobacco Cessation: An Official American Thoracic Society Research Statement
Background: Tobacco and cannabis are among the most widely used substances globally, and rates of co-use are on the rise. Understanding the impact of inhaled tobacco-cannabis co-use on health outcomes and tobacco cessation is critical for guiding patients and clinicians. Objectives: To summarize the existing evidence, identify knowledge gaps, and prioritize research questions related to effects of inhaled tobacco-cannabis co-use on tobacco cessation and lung health. Methods: A multidisciplinary committee was convened to review the evidence, identify knowledge gaps, and develop research questions in four priority research areas: 1) common data elements and terminology, 2) patterns and prevalence of co-use, 3) impact of co-use on tobacco cessation, and 4) effects of co-use on lung health. A modified Delphi process was conducted in three rounds to reach consensus on prioritizing research questions. Results: The evidence reviewed by the expert panel in four priority research areas yielded the following gaps in the literature with high priority to address with future research: 1) lack of consensus on terminology and recommended co-use data elements, 2) limited research on co-use and tobacco-related disparities, 3) insufficient evidence on how cannabis use affects tobacco cessation, and 4) alarming yet inconsistent findings on the effects of co-use on lung health. Conclusions: This statement outlines and guides a research agenda on the effects of inhaled tobacco-cannabis co-use on tobacco cessation and lung health. Consensus-driven recommendations include adopting harmonized terms and minimum data elements, studying the prevalence of co-use among populations experiencing tobacco-related disparities, evaluating the impact of co-use on tobacco cessation pharmacotherapies, and assessing the effects of co-use on the development and progression of lung diseases.
- 1 November 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (11) , 2021-2042
Open AccessEffects of Inhaled Tobacco and Cannabis Co-Use on Respiratory Health and Tobacco Cessation: An Official American Thoracic Society Research Statement
Background: Tobacco and cannabis are among the most widely used substances globally, and rates of co-use are on the rise. Understanding the impact of inhaled tobacco-cannabis co-use on health outcomes and tobacco cessation is critical for guiding patients and clinicians. Objectives: To summarize the existing evidence, identify knowledge gaps, and prioritize research questions related to effects of inhaled tobacco-cannabis co-use on tobacco cessation and lung health. Methods: A multidisciplinary committee was convened to review the evidence, identify knowledge gaps, and develop research questions in four priority research areas: 1) common data elements and terminology, 2) patterns and prevalence of co-use, 3) impact of co-use on tobacco cessation, and 4) effects of co-use on lung health. A modified Delphi process was conducted in three rounds to reach consensus on prioritizing research questions. Results: The evidence reviewed by the expert panel in four priority research areas yielded the following gaps in the literature with high priority to address with future research: 1) lack of consensus on terminology and recommended co-use data elements, 2) limited research on co-use and tobacco-related disparities, 3) insufficient evidence on how cannabis use affects tobacco cessation, and 4) alarming yet inconsistent findings on the effects of co-use on lung health. Conclusions: This statement outlines and guides a research agenda on the effects of inhaled tobacco-cannabis co-use on tobacco cessation and lung health. Consensus-driven recommendations include adopting harmonized terms and minimum data elements, studying the prevalence of co-use among populations experiencing tobacco-related disparities, evaluating the impact of co-use on tobacco cessation pharmacotherapies, and assessing the effects of co-use on the development and progression of lung diseases.
- 22 April 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 272, 112678
Using a loose-leaf vaporizer to study tobacco-cannabis co-administration: A proof-of-concept study
- 22 April 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 272, 112678
Using a loose-leaf vaporizer to study tobacco-cannabis co-administration: A proof-of-concept study
- 15 April 2023
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 25 (8) , 1489-1495
Nicotine Intake in Adult Pod E-cigarette Users: Impact of User and Device Characteristics
Introduction: This study examined user behavior, e-cigarette dependence, and device characteristics on nicotine intake among users of pod-mod e-cigarettes. Aims and Methods: In 2019–2020, people who use pod-mods in the San Francisco Bay Area completed questionnaires and provided a urine sample for analysis of total nicotine equivalents (TNE). The relationship between TNE and e-cigarette use, e-cigarette brands, e-liquid nicotine strength, e-cigarette dependence, and urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), as a measure of combustible cigarette exposure, were examined. Results: Of 100 participants (64% male, 71% in the 18–34 age group, 45% white), 53 used JUUL primarily, 12 used Puff Bar primarily, and 35 used other brands, including Suorin; 48 participants reported current cigarette smoking. Participants most often reported use of e-liquid with 4.5%–6.0% nicotine (68%), fruit (35%), tobacco (28%), and menthol or mint flavors (26%), used e-cigarettes on 25.5 (SD = 6.3) days a month, 10.2 (SD = 14.2) times a day, and 40% used 1–2 pods/cartridges per week. In bivariate analysis, urinary TNE was higher with greater frequency (days used) and intensity (number of pods used) of e-cigarette use, e-cigarette dependence, and combustible cigarette use. In multivariable analysis, days of e-cigarette use in the last 30 days, number of pods used per week, and NNAL levels were significantly associated with TNE. There was no significant impact of e-liquid nicotine strength on TNE. Conclusions: Nicotine intake among people who used pod-mod e-cigarettes increased with e-cigarette consumption and e-cigarette dependence, but not with e-liquid nicotine strength. Our findings may inform whether FDA adopts a nicotine standard for e-cigarettes. Implications: The study examined how device and user characteristics influence nicotine intake among pod-mod e-cigarette users. Nicotine intake increased with frequency (days of e-cigarette use in past 30 days) intensity of use (number of pods used per day) and e-cigarette dependence but not with the flavor or nicotine concentration of the e-liquids. Regulation of nicotine concentration of e-liquids is unlikely to influence nicotine exposure among adult experienced pod-mod users.
- 15 April 2023
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 25 (8) , 1489-1495
Nicotine Intake in Adult Pod E-cigarette Users: Impact of User and Device Characteristics
Introduction: This study examined user behavior, e-cigarette dependence, and device characteristics on nicotine intake among users of pod-mod e-cigarettes. Aims and Methods: In 2019–2020, people who use pod-mods in the San Francisco Bay Area completed questionnaires and provided a urine sample for analysis of total nicotine equivalents (TNE). The relationship between TNE and e-cigarette use, e-cigarette brands, e-liquid nicotine strength, e-cigarette dependence, and urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), as a measure of combustible cigarette exposure, were examined. Results: Of 100 participants (64% male, 71% in the 18–34 age group, 45% white), 53 used JUUL primarily, 12 used Puff Bar primarily, and 35 used other brands, including Suorin; 48 participants reported current cigarette smoking. Participants most often reported use of e-liquid with 4.5%–6.0% nicotine (68%), fruit (35%), tobacco (28%), and menthol or mint flavors (26%), used e-cigarettes on 25.5 (SD = 6.3) days a month, 10.2 (SD = 14.2) times a day, and 40% used 1–2 pods/cartridges per week. In bivariate analysis, urinary TNE was higher with greater frequency (days used) and intensity (number of pods used) of e-cigarette use, e-cigarette dependence, and combustible cigarette use. In multivariable analysis, days of e-cigarette use in the last 30 days, number of pods used per week, and NNAL levels were significantly associated with TNE. There was no significant impact of e-liquid nicotine strength on TNE. Conclusions: Nicotine intake among people who used pod-mod e-cigarettes increased with e-cigarette consumption and e-cigarette dependence, but not with e-liquid nicotine strength. Our findings may inform whether FDA adopts a nicotine standard for e-cigarettes. Implications: The study examined how device and user characteristics influence nicotine intake among pod-mod e-cigarette users. Nicotine intake increased with frequency (days of e-cigarette use in past 30 days) intensity of use (number of pods used per day) and e-cigarette dependence but not with the flavor or nicotine concentration of the e-liquids. Regulation of nicotine concentration of e-liquids is unlikely to influence nicotine exposure among adult experienced pod-mod users.
- Open Access
- 3 May 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (9) , 5563
A Mixed-Methods Study on Use of Different Tobacco Products among Younger and Older Adults with Lower and Higher Levels of Nicotine Exposure in California in 2019–2020
An increasing number of tobacco products are entering the market, offering a variety of options to attain desired nicotine intake. However, little is known about the effect of this diverse marketplace on the experiences and nicotine exposure among tobacco users. A mixed-methods study examined experiences with tobacco products among individuals with relatively lower or higher levels of biomarkers of nicotine exposure. Semi-structured interviews were conducted with younger and older adults to examine tobacco use behaviors, addiction to tobacco products, and nicotine effects. Younger and older adults provided similar narratives about addiction and nicotine effects, which were similar across age groups, product types (i.e., ENDS, combustible cigarettes, or oral tobacco products), and having lower or higher nicotine exposure. Some individuals with higher nicotine exposure who switched from combustible cigarettes to another product (e.g., ENDS) found similar or greater access and perceived addiction to nicotine. Adults with higher and lower levels of nicotine exposure provided narratives consistent with features of nicotine addiction, regardless of age and products used. Availability of multiple tobacco products may be associated with greater access and exposure to nicotine. Addiction may occur at low levels of use and with non-cigarette products.
- 3 May 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (9) , 5563
Open AccessA Mixed-Methods Study on Use of Different Tobacco Products among Younger and Older Adults with Lower and Higher Levels of Nicotine Exposure in California in 2019–2020
An increasing number of tobacco products are entering the market, offering a variety of options to attain desired nicotine intake. However, little is known about the effect of this diverse marketplace on the experiences and nicotine exposure among tobacco users. A mixed-methods study examined experiences with tobacco products among individuals with relatively lower or higher levels of biomarkers of nicotine exposure. Semi-structured interviews were conducted with younger and older adults to examine tobacco use behaviors, addiction to tobacco products, and nicotine effects. Younger and older adults provided similar narratives about addiction and nicotine effects, which were similar across age groups, product types (i.e., ENDS, combustible cigarettes, or oral tobacco products), and having lower or higher nicotine exposure. Some individuals with higher nicotine exposure who switched from combustible cigarettes to another product (e.g., ENDS) found similar or greater access and perceived addiction to nicotine. Adults with higher and lower levels of nicotine exposure provided narratives consistent with features of nicotine addiction, regardless of age and products used. Availability of multiple tobacco products may be associated with greater access and exposure to nicotine. Addiction may occur at low levels of use and with non-cigarette products.
- Open Access
- 15 August 2021
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 61 (S2) , S18-S36
Clinical Pharmacology of Electronic Nicotine Delivery Systems (ENDS): Implications for Benefits and Risks in the Promotion of the Combusted Tobacco Endgame
Electronic nicotine delivery systems (ENDS) such as e‐cigarettes and heated tobacco products are novel battery‐operated devices that deliver nicotine without combustion of tobacco. Because cigarette smoking is sustained by nicotine addiction and the toxic combustion products are mainly responsible for the harmful effects of smoking, ENDS could be used to promote smoking cessation while exposing users to lower levels of toxicants compared with conventional cigarettes. The currently available evidence from clinical and observational studies indicates a potential role of e‐cigarettes as smoking cessation aids, although many continue to use e‐cigarettes long after quitting smoking. Nicotine and toxicant delivery vary considerably by device and depend on the characteristics of the e‐liquid formulation. Because smokers tend to titrate their nicotine intake to maintain their desired pharmacologic effects, device and liquid characteristics need to be considered when using ENDS as an aid to quit smoking. Factors potentially limiting their use are the currently still unknown long‐term safety of these products and concerns regarding widespread use among youth. Implications of clinical pharmacology data on ENDS for the cigarette endgame and regulation by the U.S. Food and Drug administration are discussed.
- 15 August 2021
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 61 (S2) , S18-S36
Open AccessClinical Pharmacology of Electronic Nicotine Delivery Systems (ENDS): Implications for Benefits and Risks in the Promotion of the Combusted Tobacco Endgame
Electronic nicotine delivery systems (ENDS) such as e‐cigarettes and heated tobacco products are novel battery‐operated devices that deliver nicotine without combustion of tobacco. Because cigarette smoking is sustained by nicotine addiction and the toxic combustion products are mainly responsible for the harmful effects of smoking, ENDS could be used to promote smoking cessation while exposing users to lower levels of toxicants compared with conventional cigarettes. The currently available evidence from clinical and observational studies indicates a potential role of e‐cigarettes as smoking cessation aids, although many continue to use e‐cigarettes long after quitting smoking. Nicotine and toxicant delivery vary considerably by device and depend on the characteristics of the e‐liquid formulation. Because smokers tend to titrate their nicotine intake to maintain their desired pharmacologic effects, device and liquid characteristics need to be considered when using ENDS as an aid to quit smoking. Factors potentially limiting their use are the currently still unknown long‐term safety of these products and concerns regarding widespread use among youth. Implications of clinical pharmacology data on ENDS for the cigarette endgame and regulation by the U.S. Food and Drug administration are discussed.
- Open Access
Twenty‐four‐hour subjective and pharmacological effects of ad‐libitum electronic and combustible cigarette use among dual users
Background and Aims: Relative pharmacological effects of e‐cigarettes and cigarettes during 24 hours of ad‐libitum use have not been described. In this study, 24‐hour blood plasma nicotine concentrations and 48‐hour subjective effects with use of cigarettes and e‐cigarettes were measured among dual users.Design: Two‐arm within‐subject cross‐over design with preferred e‐cigarette or cigarette ad‐libitum use over 48 hours.Setting: Hospital research ward in San Francisco, California, USA.Participants: Thirty‐six healthy dual users of e‐cigarettes and cigarettes (n = 8, 25% females).Measurements: Twenty‐four‐hour blood plasma nicotine and cotinine concentrations and 48‐hour self‐reported nicotine withdrawal symptoms and rewarding effects.Findings: Analyses used analysis of variance (ANOVA)‐based mixed models with order of product (e‐cigarette or cigarette) and product type (combustible cigarette or type of e‐cigarette) as fixed effects, and subject as a repeated effect. During a 24‐hour period, e‐cigarettes produced lower nicotine exposure than cigarettes for the majority of users, although 25% received more nicotine from e‐cigarettes, which was predicted by more frequent e‐cigarette use or greater dependence. Compared to cigarette smoking, nicotine exposure for variable‐power tank users was similar, while cig‐a‐like (t(30) = 2.71, P = 0.011, d = 0.745) and fixed‐power tank users (t(30) = 3.37, P = 0.002, d = 0.993) were exposed to less nicotine. Cigarettes were rated higher than e‐cigarettes on some desirable subjective effects (e.g. psychological reward, t(322) = 7.24 P < 0.001, d = 0.432), but withdrawal symptom reduction was comparable. No differences were found between e‐cigarette types, but Bayes factors indicate that these measures were insensitive.Conclusions: During a 24‐hour period in a hospital setting in the United States, nicotine exposure for dual users of e‐cigarettes and cigarettes was similar when using cigarettes or variable‐power tank devices only but was lower for those using cig‐a‐like or fixed‐power devices only. Despite lower nicotine levels, all types of e‐cigarette were effective in preventing withdrawal symptoms. E‐cigarettes were rated less rewarding than cigarettes.
Open AccessTwenty‐four‐hour subjective and pharmacological effects of ad‐libitum electronic and combustible cigarette use among dual users
Background and Aims: Relative pharmacological effects of e‐cigarettes and cigarettes during 24 hours of ad‐libitum use have not been described. In this study, 24‐hour blood plasma nicotine concentrations and 48‐hour subjective effects with use of cigarettes and e‐cigarettes were measured among dual users.Design: Two‐arm within‐subject cross‐over design with preferred e‐cigarette or cigarette ad‐libitum use over 48 hours.Setting: Hospital research ward in San Francisco, California, USA.Participants: Thirty‐six healthy dual users of e‐cigarettes and cigarettes (n = 8, 25% females).Measurements: Twenty‐four‐hour blood plasma nicotine and cotinine concentrations and 48‐hour self‐reported nicotine withdrawal symptoms and rewarding effects.Findings: Analyses used analysis of variance (ANOVA)‐based mixed models with order of product (e‐cigarette or cigarette) and product type (combustible cigarette or type of e‐cigarette) as fixed effects, and subject as a repeated effect. During a 24‐hour period, e‐cigarettes produced lower nicotine exposure than cigarettes for the majority of users, although 25% received more nicotine from e‐cigarettes, which was predicted by more frequent e‐cigarette use or greater dependence. Compared to cigarette smoking, nicotine exposure for variable‐power tank users was similar, while cig‐a‐like (t(30) = 2.71, P = 0.011, d = 0.745) and fixed‐power tank users (t(30) = 3.37, P = 0.002, d = 0.993) were exposed to less nicotine. Cigarettes were rated higher than e‐cigarettes on some desirable subjective effects (e.g. psychological reward, t(322) = 7.24 P < 0.001, d = 0.432), but withdrawal symptom reduction was comparable. No differences were found between e‐cigarette types, but Bayes factors indicate that these measures were insensitive.Conclusions: During a 24‐hour period in a hospital setting in the United States, nicotine exposure for dual users of e‐cigarettes and cigarettes was similar when using cigarettes or variable‐power tank devices only but was lower for those using cig‐a‐like or fixed‐power devices only. Despite lower nicotine levels, all types of e‐cigarette were effective in preventing withdrawal symptoms. E‐cigarettes were rated less rewarding than cigarettes.
- 1 February 2020
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 13 (2) , 153-162
Comparison of Systemic Exposure to Toxic and/or Carcinogenic Volatile Organic Compounds (VOC) during Vaping, Smoking, and Abstention
Comparisons of systemic exposure to toxicants during monitored cigarette smoking, electronic cigarette (e-cigarette) use, and abstention are needed to enhance our understanding of the risks of e-cigarette use (vaping). In a cross-over study, we measured 10 mercapturic acid metabolites of volatile organic compounds (VOCs) in 24-hour urine samples collected from 36 dual users (8 women) of e-cigarettes and cigarettes during 2 days of ad libitum vaping or cigarette-only use, and 2 days of enforced abstention. Concentrations of VOC metabolites were higher during smoking compared with vaping, except for the methylating agents' metabolite. The fold-difference in concentrations when smoking relative to vaping ranged from 1.31 (1.06–1.61; geometric mean, 95% confidence interval; 1,3-butadiene) to 7.09 (5.88–8.54; acrylonitrile). Metabolites of acrylamide [fold difference of 1.21 (1.03–1.43)] and benzene [1.46 (1.13–1.90)] were higher during vaping compared with abstention. The 1,3-butadiene and propylene oxide metabolites were higher in variable-power tank users compared with users of cig-a-likes. E-cigarettes expose users to lower levels of toxic VOCs compared with cigarette smoking, supporting their harm reduction potential among smokers. However, some e-cigarettes expose users to VOCs such as acrylamide, benzene, and propylene oxide, and may pose health risks to nonsmoking users. The results of our study will inform regulators in assessing e-cigarettes with respect to the balance between its potential harm reduction for adult smokers and risk to nonsmoking users.
- 1 February 2020
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 13 (2) , 153-162
Comparison of Systemic Exposure to Toxic and/or Carcinogenic Volatile Organic Compounds (VOC) during Vaping, Smoking, and Abstention
Comparisons of systemic exposure to toxicants during monitored cigarette smoking, electronic cigarette (e-cigarette) use, and abstention are needed to enhance our understanding of the risks of e-cigarette use (vaping). In a cross-over study, we measured 10 mercapturic acid metabolites of volatile organic compounds (VOCs) in 24-hour urine samples collected from 36 dual users (8 women) of e-cigarettes and cigarettes during 2 days of ad libitum vaping or cigarette-only use, and 2 days of enforced abstention. Concentrations of VOC metabolites were higher during smoking compared with vaping, except for the methylating agents' metabolite. The fold-difference in concentrations when smoking relative to vaping ranged from 1.31 (1.06–1.61; geometric mean, 95% confidence interval; 1,3-butadiene) to 7.09 (5.88–8.54; acrylonitrile). Metabolites of acrylamide [fold difference of 1.21 (1.03–1.43)] and benzene [1.46 (1.13–1.90)] were higher during vaping compared with abstention. The 1,3-butadiene and propylene oxide metabolites were higher in variable-power tank users compared with users of cig-a-likes. E-cigarettes expose users to lower levels of toxic VOCs compared with cigarette smoking, supporting their harm reduction potential among smokers. However, some e-cigarettes expose users to VOCs such as acrylamide, benzene, and propylene oxide, and may pose health risks to nonsmoking users. The results of our study will inform regulators in assessing e-cigarettes with respect to the balance between its potential harm reduction for adult smokers and risk to nonsmoking users.
Differences in nicotine intake and effects from electronic and combustible cigarettes among dual users
Aim: To describe systemic nicotine exposure and subjective effects of electronic cigarettes (e‐cigarettes) in people who use both e‐cigarettes and cigarettes (dual users), including within‐subject comparisons of e‐cigarette and cigarette use.Design: Two‐arm, counterbalanced cross‐over study. Participants used their usual brand of e‐cigarette or cigarette during a standardized session in a 2‐week study.Setting: Hospital research ward, San Francisco, CA, USA.Participants: Thirty‐six healthy (eight women, 28 men) participants.Measurements: Plasma nicotine was analyzed by gas chromatography–tandem mass spectrometry; nicotine withdrawal, urge to smoke and vape, affective states, craving, satisfaction and psychological reward were measured by standardized questionnaires.Findings: Compared with cigarettes, average maximum plasma nicotine concentration (Cmax) was lower with e‐cigarettes [6.1 ± 5.5 ng/ml, mean ± standard deviation (SD) versus 20.2 ± 11.1 ng/ml, P < 0.001] and time of maximal concentration (Tmax) was longer (6.5 ± 5.4 versus 2.7 ± 2.4 minutes, P < 0.001). Use of both products resulted in a reduction in the severity of withdrawal symptoms, negative affect and urge to use either product. E‐cigarettes were less rewarding and satisfying and reduced craving to a lesser degree than cigarettes. We were not able to detect any differences in withdrawal symptoms, affective states and urge to smoke cigarettes between e‐cigarette and cigarette use.Conclusion: Systemic nicotine exposure was, on average, lower with single use of e‐cigarettes compared with cigarettes, and e‐cigarettes were judged to be less satisfying and rewarding and reduced craving less than cigarettes.
Differences in nicotine intake and effects from electronic and combustible cigarettes among dual users
Aim: To describe systemic nicotine exposure and subjective effects of electronic cigarettes (e‐cigarettes) in people who use both e‐cigarettes and cigarettes (dual users), including within‐subject comparisons of e‐cigarette and cigarette use.Design: Two‐arm, counterbalanced cross‐over study. Participants used their usual brand of e‐cigarette or cigarette during a standardized session in a 2‐week study.Setting: Hospital research ward, San Francisco, CA, USA.Participants: Thirty‐six healthy (eight women, 28 men) participants.Measurements: Plasma nicotine was analyzed by gas chromatography–tandem mass spectrometry; nicotine withdrawal, urge to smoke and vape, affective states, craving, satisfaction and psychological reward were measured by standardized questionnaires.Findings: Compared with cigarettes, average maximum plasma nicotine concentration (Cmax) was lower with e‐cigarettes [6.1 ± 5.5 ng/ml, mean ± standard deviation (SD) versus 20.2 ± 11.1 ng/ml, P < 0.001] and time of maximal concentration (Tmax) was longer (6.5 ± 5.4 versus 2.7 ± 2.4 minutes, P < 0.001). Use of both products resulted in a reduction in the severity of withdrawal symptoms, negative affect and urge to use either product. E‐cigarettes were less rewarding and satisfying and reduced craving to a lesser degree than cigarettes. We were not able to detect any differences in withdrawal symptoms, affective states and urge to smoke cigarettes between e‐cigarette and cigarette use.Conclusion: Systemic nicotine exposure was, on average, lower with single use of e‐cigarettes compared with cigarettes, and e‐cigarettes were judged to be less satisfying and rewarding and reduced craving less than cigarettes.